Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 12/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.63 |
| ▸ | RET | P07949 | 4/20 | 0.63 |
| ▸ | BRAF | P15056 | 3/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.63 |
| ▸ | ABL1 | P00519 | 3/20 | 0.63 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.63 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 2/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.63 |
| ▸ | LCK | P06239 | 2/20 | 0.63 |
| ▸ | FYN | P06241 | 2/20 | 0.63 |
| ▸ | LYN | P07948 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.63 |
| ▸ | AXL | P30530 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946030 | 0.92 | RET (0.65) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL13946016 | 0.92 | RAF1 (0.61) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL4211673 | 0.90 | RAF1 (0.59) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL4209263 | 0.88 | RAF1 (0.82) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL14067061 | 0.88 | KDR (0.61) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL4205874 | 0.87 | KDR (0.60) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL4205893 | 0.85 | RAF1 (0.59) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL13946029 | 0.84 | KMO (0.52) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL4205884 | 0.84 | KDR (0.56) | RAF1KDRRETBRAFEPHX2 | |
| SCHEMBL13946011 | 0.84 | RET (0.62) | RAF1KDRRETBRAFEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | KINAGEN, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012091-A1 | Oximide derivatives and their therapeutical application | CYP11B2, NOS2, HMOX2 | RAF1 3755/4885KDR 1151/4885RET 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.